The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells

Carcinogenesis

Volumn 33, Issue 10, 2012, Pages 1871-1881

  Tseng, Hsin Yi ^a,b   Chen, Li Hua ^a,b   Ye, Yan ^a,b   Tay, Kwang Hong ^a,b   Jiang, Chen Chen ^a,b   Guo, Su Tang ^c   Jin, Lei ^d   Hersey, Peter ^d   Zhang, Xu Dong ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^c SHANXI CANCER HOSPITAL   (China)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 5; MELANOMA ANTIGEN; MELANOMA ANTIGEN D2; PROTEIN P53; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; GENES, P53; HUMANS; MELANOMA; NEOPLASM PROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SKIN NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 84867289331     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs236     Document Type: Article

References (51)

1. Simpson, A.J. et al. (2005) Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer, 5, 615-625.
2. Sang, M. et al. (2011) Melanoma-associated antigen genes - an update. Cancer Lett., 302, 85-90.
3. Fratta, E. et al. (2011) The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol. Oncol., 5, 164-182.
4. Scanlan, M.J. et al. (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev., 188, 22-32.
5. Chomez, P. et al. (2001) An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res., 61, 5544-5551.
6. Acres, B. et al. (2002) Tumor immunology and the Battle of Waterloo. Mol. Cancer Ther., 1, 651-655.
7. Corbiere, V. et al. (2011) Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res., 71, 1253-1262.
8. Costa, F.F. et al. (2007) Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells, 25, 707-711.
9. Nardiello, T. et al. (2011) MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin. Cancer Res., 17, 4309-4319.
10. Yang, B. et al. (2007) Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J. Invest. Dermatol., 127, 267-275.
11. Xiao, T.Z. et al. (2011) MAGE I transcription factors regulate KAP1 and KRAB domain zinc finger transcription factor mediated gene repression. PLoS One, 6, e23747.
12. Doyle, J.M. et al. (2010) MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol. Cell, 39, 963-974.
13. Monte, M. et al. (2006) MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl Acad. Sci. USA, 103, 11160-11165.
14. Taniura, H. et al. (1999) Physical and functional interactions of neuronal growth suppressor necdin with p53. J. Biol. Chem., 274, 16242-16248.
15. Yang, B. et al. (2007) MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res., 67, 9954-9962.
16. Curioni-Fontecedro, A. et al. (2011) Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. PLoS One, 6, e21418.
17. Germano, S. et al. (2011) MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int. J. Cancer., 130, 1991-2002.
18. Svobodova, S. et al. (2011) Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Eur. J. Cancer, 47, 460-469.
19. Zhang, X.D. et al. (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett., 482, 193-199.
20. Johnstone, R.W. et al. (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer, 8, 782-798.
21. Ashkenazi, A. et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest., 104, 155-162.
22. Walczak, H. et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med., 5, 157-163.
23. Ashkenazi, A. et al. (1999) Apoptosis control by death and decoy receptors. Curr. Opin. Cell. Biol., 11, 255-260.
24. Bellail, A.C. et al. (2009) TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials, 4, 34-41.
25. Wiezorek, J. et al. (2010) Death receptor agonists as a targeted therapy for cancer. Clin. Cancer Res., 16, 1701-1708.
26. Zhang, X.D. et al. (1999) Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res., 59, 2747-2753.
27. Nguyen, T. et al. (2001) Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin. Cancer Res., 7, 966s-973s.
28. Zhang, X.Y. et al. (2004) Translational control of tumor necrosis factor-related apoptosis-inducing ligand death receptor expression in melanoma cells. J. Biol. Chem., 279, 10606-10614.
29. Zhuang, L. et al. (2006) Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum. Pathol., 37, 1286-1294.
30. Jiang, C.C. et al. (2007) Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res., 67, 5880-5888.
31. Tseng, H.Y. et al. (2010) Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells. Mol. Cancer Ther., 9, 3363-3374.
32. Liu, H. et al. (2009) 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2. Mol. Cancer, 8, 122.
33. Wlodkowic, D. et al. (2011) Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol., 103, 55-98.
34. Yang, F. et al. (2010) Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. Cell Death Differ., 17, 1354-1367.
35. Jin, L. et al. (2011) MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc. Natl Acad. Sci. USA., 108, 15840-15845.
36. Zhang, X.D. et al. (2001) Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res., 61, 7339-7348.
37. Jiang, C.C. et al. (2011) MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin. Cancer Res., 17, 721-730.
38. Jiang, C.C. et al. (2010) Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis., 1, e69.
39. Avery-Kiejda, K.A. et al. (2008) Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin. Cancer Res., 14, 1659-1668.
40. Hersey, P. et al. (2001) How melanoma cells evade trail-induced apoptosis. Nat. Rev. Cancer, 1, 142-150.
41. Jiang, C.C. et al. (2008) Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res., 68, 6708-6717.
42. Nguyen, T. et al. (2000) Immunologically-mediated tumour cell apoptosis: the role of TRAIL in T cell and cytokine-mediated responses to melanoma. Forum (Genova), 10, 243-252.
43. Smyth, M.J. et al. (2003) Nature's TRAIL--on a path to cancer immunotherapy. Immunity, 18, 1-6.
44. Wu, G.S. et al. (1997) KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet., 17, 141-143.
45. Riley, T. et al. (2008) Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol., 9, 402-412.
46. Murray-Zmijewski, F. et al. (2008) A complex barcode underlies the heterogeneous response of p53 to stress. Nat. Rev. Mol. Cell Biol., 9, 702-712.
47. Tomso, D.J. et al. (2005) Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc. Natl Acad. Sci. USA, 102, 6431-6436.
48. Papageorgio, C. et al. (2007) MAGED2: a novel p53-dissociator. Int. J. Oncol., 31, 1205-1211.
49. Kannengiesser, C. et al. (2008) Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol. Oncol., 1, 425-430.
50. Hoek, K.S. et al. (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res., 19, 290-302.
51. Pavey, S. et al. (2004) Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene, 23, 4060-4067.